Industry & Policy News

[Scinus Group] Scinus Group, a Utrecht-based startup that develops and distributes bioreactor technology for stem cell cultivation, has closed a €3 million strategic investment round to accelerate the global rollout of the Osilaris^™ cell expansion platform.

[Bristol Myers Squibb (Business Wire)] Bristol Myers Squibb announced that the US FDA has approved Sotyktu^® (deucravacitinib) for the treatment of adults with active psoriatic arthritis.

[Citius Oncology, Inc.] Citius Oncology, Inc. announced positive topline results from a completed investigator‑initiated Phase I clinical trial evaluating the direct Treg cell depletion activity of LYMPHIR™ in combination with the PD-1 immune checkpoint inhibitor pembrolizumab in patients with recurrent or refractory gynecologic cancers.

[Pilatus Biosciences, Inc.] Pilatus Biosciences, Inc. announced the first patient has been dosed in its Phase I clinical trial evaluating PLT012, a first-in-class anti-CD36 monoclonal antibody for the treatment of advanced solid tumors.

[Quell Therapeutics Ltd ] Quell Therapeutics Ltd announced that it has initiated a Phase I/II basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients with Rheumatoid Arthritis and Systemic Sclerosis – the “CHILL” study.

[Hepion Pharmaceuticals, Inc.] Hepion Pharmaceuticals, Inc. announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA to facilitate early diagnosis of HCC in high-risk patients.